Cross-Reactive Immunity to Clade 2 Strains of Influenza Virus A Subtype H5N1 Induced in Adults and Elderly Patients by Fluval, a Prototype Pandemic Influenza Virus Vaccine Derived by Reverse Genetics, Formulated with a Phosphate Adjuvant, and Directed to Clade 1 Strains

Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CVI About CVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...

Full description

Saved in:
Bibliographic Details
Published inClinical and Vaccine Immunology Vol. 16; no. 4; pp. 437 - 443
Main Authors Fazekas, György, Martosne-Mendi, Rita, Jankovics, Istvan, Szilvasy, Istvan, Vajo, Zoltan
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.04.2009
American Society for Microbiology (ASM)
Subjects
Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - pharmacology
Adult
Aged
Aged, 80 and over
Aluminum Compounds - administration & dosage
Aluminum Compounds - pharmacology
Antibodies, Viral - blood
Disease Outbreaks - prevention & control
Female
Hemagglutination Inhibition Tests
Hemagglutinins, Viral - genetics
Humans
Influenza A virus
Influenza A Virus, H5N1 Subtype - genetics
Influenza A Virus, H5N1 Subtype - immunology
Influenza Vaccines - genetics
Influenza Vaccines - immunology
Influenza virus
Influenza, Human - prevention & control
Male
Middle Aged
Phosphates - administration & dosage
Phosphates - pharmacology
Phylogeny
Vaccine Research
Young Adult
Online AccessGet full text
ISSN1556-6811
1556-679X
1556-679X
DOI10.1128/CVI.00327-08

Cover

Abstract Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CVI About CVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy CVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 1556-6811 Online ISSN: 1556-679X Copyright © 2014 by the American Society for Microbiology.   For an alternate route to CVI .asm.org, visit: CVI       
AbstractList High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 kg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.
High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 μg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.
High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 microg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.
High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 microg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 microg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.
Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CVI About CVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy CVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 1556-6811 Online ISSN: 1556-679X Copyright © 2014 by the American Society for Microbiology.   For an alternate route to CVI .asm.org, visit: CVI       
Author Rita Martosne-Mendi
Zoltan Vajo
Istvan Szilvasy
Istvan Jankovics
György Fazekas
AuthorAffiliation Omninvest Ltd., Pilisborosjeno, 1 National Institute of Epidemiology, 2 State Health Center, Budapest, Hungary 3
AuthorAffiliation_xml – name: Omninvest Ltd., Pilisborosjeno, 1 National Institute of Epidemiology, 2 State Health Center, Budapest, Hungary 3
Author_xml – sequence: 1
  givenname: György
  surname: Fazekas
  fullname: Fazekas, György
  organization: Omninvest Ltd., Pilisborosjeno, National Institute of Epidemiology, State Health Center, Budapest, Hungary
– sequence: 2
  givenname: Rita
  surname: Martosne-Mendi
  fullname: Martosne-Mendi, Rita
  organization: Omninvest Ltd., Pilisborosjeno, National Institute of Epidemiology, State Health Center, Budapest, Hungary
– sequence: 3
  givenname: Istvan
  surname: Jankovics
  fullname: Jankovics, Istvan
  organization: Omninvest Ltd., Pilisborosjeno, National Institute of Epidemiology, State Health Center, Budapest, Hungary
– sequence: 4
  givenname: Istvan
  surname: Szilvasy
  fullname: Szilvasy, Istvan
  organization: Omninvest Ltd., Pilisborosjeno, National Institute of Epidemiology, State Health Center, Budapest, Hungary
– sequence: 5
  givenname: Zoltan
  surname: Vajo
  fullname: Vajo, Zoltan
  organization: Omninvest Ltd., Pilisborosjeno, National Institute of Epidemiology, State Health Center, Budapest, Hungary
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19020111$$D View this record in MEDLINE/PubMed
BookMark eNqFkktvEzEUhQdURB_AijUyG1ZJsT0Pz2yQorRpI1UQtRCxszyeO40rjx1sT6rw63GSpryEWNny_e7xufY5Tg6MNZAkrwk-JYSW78fz6SnGKWVDXD5NjkieF8OCVV8P9vuSkMPk2Ps7jLO0KNnz5JBUmGJCyNGTV2NnvR9eg5BBrQBNu643KqxRsGisRQOIopvghDIe2RZNTat7MN8FmivXezRCN30d1ktAl_lHEstNL6FByqBR0-vgkTANOtcNOL1GMxEUmHhYr9FE9yuhB0igmbPBbiVmEYZOyb9umQsplQF0Bi56bDb917AC5wFdgIGgpB-giXVdr0WI9XsVFhvlhfXLRTyJZu7idSYMtn7OlAO54R5nJPsZXyTPWqE9vHxYT5Ivk_PP48vh1aeL6Xh0NZRZWoUh5BWjZVtRWhdAWlFL2uQyZxTTBteyrAmjpCzKLC_SluS1ZFlWN6JOi0oyoG16knzY6S77uoNGxmdxQvOlU51wa26F4r9XjFrwW7vitChKylgUePcg4Oy3HnzgnfIStBYGbO95wWI2GMH_BSnJKlblVQTf_Grp0cs-KxEY7AC5iYyD9ieC-SaKPEaRb6PIcRlx-gcuVYgJsJuBlP5X09td00LdLu7jP3HhOy4brTgpeMazlKU_AIpc7_w
CitedBy_id crossref_primary_10_2222_jsv_60_69
crossref_primary_10_1007_s00705_013_1754_z
crossref_primary_10_1128_JVI_01894_09
crossref_primary_10_1208_s12248_010_9179_z
crossref_primary_10_1016_S1473_3099_09_70153_7
crossref_primary_10_1016_j_virusres_2013_05_006
crossref_primary_10_3390_v13030500
crossref_primary_10_1017_S1462399410001432
crossref_primary_10_1111_bcp_13289
crossref_primary_10_1128_CVI_00096_13
crossref_primary_10_1128_CVI_05619_11
crossref_primary_10_1586_erv_09_25
crossref_primary_10_1016_S0140_6736_09_62039_0
crossref_primary_10_1016_j_cll_2009_10_005
crossref_primary_10_2217_fvl_15_69
crossref_primary_10_3390_v16111671
crossref_primary_10_3390_vaccines9121465
Cites_doi 10.1128/JVI.75.11.5141-5150.2001
10.3201/eid1305.061248
10.1038/nature04795
10.1128/JCM.37.4.937-943.1999
10.1086/505225
10.1016/S0140-6736(07)61297-5
10.1016/S0092-1157(77)80008-5
10.3201/eid1401.061283
10.1056/NEJMoa060930
10.1056/NEJMp068205
10.3201/eid1110.050644
10.1016/j.vaccine.2007.01.083
10.1086/521304
10.1016/j.vaccine.2006.05.039
10.1016/j.vaccine.2007.07.027
10.1128/jcm.23.2.240-245.1986
10.1073/pnas.0601266103
ContentType Journal Article
Copyright Copyright © 2009, American Society for Microbiology
Copyright_xml – notice: Copyright © 2009, American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
8FD
FR3
H94
P64
RC3
7X8
5PM
DOI 10.1128/CVI.00327-08
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Genetics Abstracts

MEDLINE
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1556-679X
EndPage 443
ExternalDocumentID PMC2668277
19020111
10_1128_CVI_00327_08
cdli_16_4_437
Genre Journal Article
GroupedDBID ---
.GJ
0R~
29B
2WC
39C
4.4
53G
5GY
5VS
AAFWJ
AAGFI
AAUOK
AAYXX
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
H13
HYE
HZ~
KQ8
O9-
RHI
RNS
RPM
RSF
TR2
W2D
W8F
WOQ
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
8FD
FR3
H94
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c439t-e59728f922b6e1fabc2d5c57202d0bc8b17218684563f15bc744bdab369c7e2f3
ISSN 1556-6811
1556-679X
IngestDate Thu Aug 21 14:30:01 EDT 2025
Fri Sep 05 10:07:37 EDT 2025
Fri Sep 05 08:00:56 EDT 2025
Thu May 22 04:42:36 EDT 2025
Thu Apr 24 22:55:41 EDT 2025
Tue Jul 01 03:05:37 EDT 2025
Wed May 18 15:27:18 EDT 2016
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c439t-e59728f922b6e1fabc2d5c57202d0bc8b17218684563f15bc744bdab369c7e2f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Corresponding author. Mailing address: State Health Center, Varosmajor u. 49, Budapest 1122, Hungary. Phone: 36 70 948 9731. Fax: 36 23 360 566. E-mail: zoltanvajo@gmail.com
OpenAccessLink https://doi.org/10.1128/cvi.00327-08
PMID 19020111
PQID 21497959
PQPubID 23462
PageCount 7
ParticipantIDs crossref_primary_10_1128_CVI_00327_08
pubmed_primary_19020111
proquest_miscellaneous_67128710
highwire_asm_cdli_16_4_437
crossref_citationtrail_10_1128_CVI_00327_08
proquest_miscellaneous_21497959
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2668277
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-04-01
PublicationDateYYYYMMDD 2009-04-01
PublicationDate_xml – month: 04
  year: 2009
  text: 2009-04-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical and Vaccine Immunology
PublicationTitleAlternate Clin Vaccine Immunol
PublicationYear 2009
Publisher American Society for Microbiology
American Society for Microbiology (ASM)
Publisher_xml – name: American Society for Microbiology
– name: American Society for Microbiology (ASM)
References (e_1_3_1_27_2) 2005; 11
(e_1_3_1_6_2) 2007
(e_1_3_1_25_2) 2006; 355
(e_1_3_1_11_2) 2007; 196
(e_1_3_1_12_2) 2006; 355
e_1_3_1_21_2
(e_1_3_1_14_2) 2003
e_1_3_1_22_2
(e_1_3_1_23_2) 2007; 13
e_1_3_1_24_2
(e_1_3_1_20_2) 1952; 3
e_1_3_1_4_2
e_1_3_1_3_2
(e_1_3_1_10_2) 2006; 194
e_1_3_1_5_2
(e_1_3_1_2_2) 2007; 25
(e_1_3_1_9_2) 2008; 14
(e_1_3_1_16_2) 2006; 24
e_1_3_1_13_2
(e_1_3_1_7_2) 2006; 442
(e_1_3_1_8_2) 2006; 103
(e_1_3_1_18_2) 1938; 27
(e_1_3_1_17_2) 2007; 25
e_1_3_1_15_2
(e_1_3_1_26_2) 1977; 5
e_1_3_1_19_2
16642006 - Nature. 2006 Jul 27;442(7101):448-52
17293015 - Vaccine. 2007 May 4;25(18):3554-60
17719149 - Vaccine. 2007 Sep 28;25(39-40):6852-62
10074505 - J Clin Microbiol. 1999 Apr;37(4):937-43
17124014 - N Engl J Med. 2006 Nov 23;355(21):2174-7
16779721 - J Infect Dis. 2006 Jul 15;194(2):159-67
16585506 - Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40
17030078 - Vaccine. 2006 Nov 10;24(44-46):6588-93
3517049 - J Clin Microbiol. 1986 Feb;23(2):240-5
11333895 - J Virol. 2001 Jun;75(11):5141-50
18044056 - Emerg Infect Dis. 2007 May;13(5):807-8
16318689 - Emerg Infect Dis. 2005 Oct;11(10):1515-21
17124016 - N Engl J Med. 2006 Nov 23;355(21):2186-94
408355 - J Biol Stand. 1977;5(3):237-47
13007362 - Acta Med Acad Sci Hung. 1952;3(2):185-91
18258091 - Emerg Infect Dis. 2008 Jan;14(1):121-8
17922395 - J Infect Dis. 2007 Nov 1;196(9):1313-20
17707753 - Lancet. 2007 Aug 18;370(9587):580-9
References_xml – ident: e_1_3_1_21_2
  doi: 10.1128/JVI.75.11.5141-5150.2001
– start-page: 3406
  year: 2007
  ident: e_1_3_1_6_2
  publication-title: European pharmacopeia
– volume: 13
  start-page: 807
  year: 2007
  ident: e_1_3_1_23_2
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid1305.061248
– ident: e_1_3_1_4_2
– volume: 442
  start-page: 448
  year: 2006
  ident: e_1_3_1_7_2
  publication-title: Nature
  doi: 10.1038/nature04795
– start-page: 1
  year: 2003
  ident: e_1_3_1_14_2
  publication-title: In Influenza laboratory course.
– ident: e_1_3_1_19_2
  doi: 10.1128/JCM.37.4.937-943.1999
– ident: e_1_3_1_3_2
– volume: 194
  start-page: 159
  year: 2006
  ident: e_1_3_1_10_2
  publication-title: J. Infect. Dis.
  doi: 10.1086/505225
– ident: e_1_3_1_15_2
  doi: 10.1016/S0140-6736(07)61297-5
– volume: 5
  start-page: 237
  year: 1977
  ident: e_1_3_1_26_2
  publication-title: J. Biol. Stand.
  doi: 10.1016/S0092-1157(77)80008-5
– volume: 14
  start-page: 121
  year: 2008
  ident: e_1_3_1_9_2
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid1401.061283
– volume: 355
  start-page: 2186
  year: 2006
  ident: e_1_3_1_12_2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa060930
– volume: 355
  start-page: 2174
  year: 2006
  ident: e_1_3_1_25_2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMp068205
– volume: 11
  start-page: 1515
  year: 2005
  ident: e_1_3_1_27_2
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid1110.050644
– volume: 25
  start-page: 3554
  year: 2007
  ident: e_1_3_1_17_2
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2007.01.083
– volume: 3
  start-page: 185
  year: 1952
  ident: e_1_3_1_20_2
  publication-title: Acta Med. Acad. Sci. Hung.
– ident: e_1_3_1_5_2
– volume: 196
  start-page: 1313
  year: 2007
  ident: e_1_3_1_11_2
  publication-title: J. Infect. Dis.
  doi: 10.1086/521304
– ident: e_1_3_1_22_2
– ident: e_1_3_1_13_2
– volume: 24
  start-page: 6588
  year: 2006
  ident: e_1_3_1_16_2
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.05.039
– volume: 25
  start-page: 6852
  year: 2007
  ident: e_1_3_1_2_2
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2007.07.027
– volume: 27
  start-page: 493
  year: 1938
  ident: e_1_3_1_18_2
  publication-title: Am. J. Hyg.
– ident: e_1_3_1_24_2
  doi: 10.1128/jcm.23.2.240-245.1986
– volume: 103
  start-page: 5935
  year: 2006
  ident: e_1_3_1_8_2
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0601266103
– reference: 16585506 - Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40
– reference: 17719149 - Vaccine. 2007 Sep 28;25(39-40):6852-62
– reference: 11333895 - J Virol. 2001 Jun;75(11):5141-50
– reference: 18258091 - Emerg Infect Dis. 2008 Jan;14(1):121-8
– reference: 17124016 - N Engl J Med. 2006 Nov 23;355(21):2186-94
– reference: 13007362 - Acta Med Acad Sci Hung. 1952;3(2):185-91
– reference: 408355 - J Biol Stand. 1977;5(3):237-47
– reference: 3517049 - J Clin Microbiol. 1986 Feb;23(2):240-5
– reference: 18044056 - Emerg Infect Dis. 2007 May;13(5):807-8
– reference: 16318689 - Emerg Infect Dis. 2005 Oct;11(10):1515-21
– reference: 17922395 - J Infect Dis. 2007 Nov 1;196(9):1313-20
– reference: 16642006 - Nature. 2006 Jul 27;442(7101):448-52
– reference: 17124014 - N Engl J Med. 2006 Nov 23;355(21):2174-7
– reference: 17293015 - Vaccine. 2007 May 4;25(18):3554-60
– reference: 16779721 - J Infect Dis. 2006 Jul 15;194(2):159-67
– reference: 17707753 - Lancet. 2007 Aug 18;370(9587):580-9
– reference: 10074505 - J Clin Microbiol. 1999 Apr;37(4):937-43
– reference: 17030078 - Vaccine. 2006 Nov 10;24(44-46):6588-93
SSID ssj0043687
Score 1.9951054
Snippet Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit...
High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious,...
SourceID pubmedcentral
proquest
pubmed
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 437
SubjectTerms Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - pharmacology
Adult
Aged
Aged, 80 and over
Aluminum Compounds - administration & dosage
Aluminum Compounds - pharmacology
Antibodies, Viral - blood
Disease Outbreaks - prevention & control
Female
Hemagglutination Inhibition Tests
Hemagglutinins, Viral - genetics
Humans
Influenza A virus
Influenza A Virus, H5N1 Subtype - genetics
Influenza A Virus, H5N1 Subtype - immunology
Influenza Vaccines - genetics
Influenza Vaccines - immunology
Influenza virus
Influenza, Human - prevention & control
Male
Middle Aged
Phosphates - administration & dosage
Phosphates - pharmacology
Phylogeny
Vaccine Research
Young Adult
Title Cross-Reactive Immunity to Clade 2 Strains of Influenza Virus A Subtype H5N1 Induced in Adults and Elderly Patients by Fluval, a Prototype Pandemic Influenza Virus Vaccine Derived by Reverse Genetics, Formulated with a Phosphate Adjuvant, and Directed to Clade 1 Strains
URI http://cvi.asm.org/content/16/4/437.abstract
https://www.ncbi.nlm.nih.gov/pubmed/19020111
https://www.proquest.com/docview/21497959
https://www.proquest.com/docview/67128710
https://pubmed.ncbi.nlm.nih.gov/PMC2668277
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9NAFB5oEYgDCMqWQmEOcEpd7Im3HKuooa3agrqpN2tmYqumwa5iJ1Ly63lvljjpIpZLFNmT8ZvM9-Ytfgshn10ZZXHccbF7Wej4MfOcWAjuwOABmBOSdyS6Bg6Pwt0zf_8iuHi4srEQtTSuxZac3ZlX8j-7CtdgXzFL9h92dj4pXIDvsL_wCTsMn3-1xz0Ucc5xytWh1d5TuR610id7Qz5A3-qJ6gFR6YwR1Y9kxtvn-WhcwZEAp4Zywe4GR14bm3hgMAA6QLAohy7evINdvIdTLOWfq2Q4UFf7w_FE9Qloc0w0qEs1yQ90R2Ok_c3nnHOJb-_haBsBlUrhPU4xGkQXva5NqFIftGfsJWbj4WHuy7K6voQrQNBPeKQukaBip9VBDSPnK_XsShe17Z5N-8TfTAwZOf5LSy8T-nyWXunEtm_TEnMhGz_9qC6rInUO02KQ60IE9VyQ7fPiqpwY8veqetJw2sksH054Nb1xx7pXugtROUYiBKETRqrfbyMywgXW8BfOf19XsDGqhK8rUN2WUgwzL3rne1twprLIceNGGtsIhKPvSf_s4CA53bk4XSGPWASqoXVGaUUDeweo3kGWQpvXweKvi3Mva1y2CvZdFtXNwOAFTev0BXluTCS6rfH-kjxMizXyWDdNna6RJ4cmHOTVg2fLDEAtA9C6pAoWlFEDC1pmdA5MqoBJt6lhAIoMQA0D0LygmgEowIYaBqCWAaiYUs0Am5TTOfyphf-tpxj4UwN__L2BP7Xw36QN-CmCH2e24KcW_JuKHgv9Zo2eXeNrctbfOe3tOqbBiSPBDqidFKx5FmddxkSYehkXkg0CGUTMZQNXyFigfyYOYzByOpkXCBn5vhhw0Qm7MkpZ1nlDVouySN8RKmIRMLgfCu75POOxkG7GZea7HeGFzGuRtgVBIk31f6RtmCgvAIsTgEyiIJO4cYt8mY--1lVv7hm3bvGU8OpXIgfDPPHCxE-AEVrkk0VYAjILX0TyIi3HVcI8kAzdoHv_iDDy0JXjtshbjciGjK6LNgssKFrC6nwA1stfvlPkl6puPtgiMYui9T_S9Z48bY6CD2S1Ho3TDbA9avFRceBv57E7MQ
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cross-Reactive+Immunity+to+Clade+2+Strains+of+Influenza+Virus+A+Subtype+H5N1+Induced+in+Adults+and+Elderly+Patients+by+Fluval%2C+a+Prototype+Pandemic+Influenza+Virus+Vaccine+Derived+by+Reverse+Genetics%2C+Formulated+with+a+Phosphate+Adjuvant%2C+and+Directed+to+Clade+1+Strains&rft.jtitle=Clinical+and+vaccine+immunology&rft.au=Fazekas%2C+Gyoergy&rft.au=Martosne-Mendi%2C+Rita&rft.au=Jankovics%2C+Istvan&rft.au=Szilvasy%2C+Istvan&rft.date=2009-04-01&rft.issn=1556-679X&rft.volume=16&rft.issue=4&rft.spage=437&rft.epage=443&rft_id=info:doi/10.1128%2FCVI.00327-08&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-6811&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-6811&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-6811&client=summon